×

Neurocrine Biosciences CEO on TD treatment

2:35 PM ET Tue, 7 Jan 2014

Neurocrine Biosciences' president and CEO Kevin Gorman, Ph. D., provides insight on clinical trials for its tardive dyskinesia treatment.